search for
Simulation Study on the Feasibility of Using Heavier Ions in Charged Particle Therapy
New Phys.: Sae Mulli 2017; 67: 1445~1449
Published online December 29, 2017;
© 2017 New Physics: Sae Mulli.

Jong-Kwan WOO1, Jewou KO1, Sue Lynn LEE2, Dong LIU*1,3

1 Department of Physics, Jeju National University, Jeju 63243, Korea 
2 Division of Engineering, Cambridge University, Cambridgeshire, England
3 Medical Physics Laboratory, Jeju National University, Jeju 63243, Korea 
Correspondence to:
Received September 8, 2017; Revised October 28, 2017; Accepted October 28, 2017.
cc This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Proton therapy is a type of advanced radiotherapy that applies a high-energy proton beam to kill target cells by using the special physical properties of protons. In some institutes, instead of proton beams, carbon-ion beams are also utilized due to carbon ions having more ideal physical properties than protons. According to the interaction principle of particles of matter, a heavy ion, such as oxygen ions or heavier ions, could produce a sharper Bragg peak. In other words, heavy ions may show advantages in the dose distribution in comparison to protons or carbon ions. In order to confirm this, we used the Monte Carlo method to simulate the radiotherapy using various heavy ions, and we calculated the dose in the target volume and the normal volumes. The results show that the heavier ion will deposit a higher energy the target volume in the case of the same dose deposition in the normal volumes. In conclusion, in particle radiotherapy, a heavier ion could provide a more ideal physical dose distribution compared to those of protons and carbon.
PACS numbers: 29.90.+r, 87.10.Rt, 87.56.-v
Keywords: Radiation therapy, Charged particle therapy, Monte Carlo simulation

December 2017, 67 (12)
  • Scopus
  • CrossMark